Design Therapeutics, Inc. Financials
Design Therapeutics, Inc. (DSGN) reported $0 in revenue for fiscal year 2025. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 6 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Design Therapeutics remains a cash-consuming development platform, financed through new equity while preserving a debt-light balance sheet.
FY2025 reads as a funding cadence problem: operating cash burn of$54.4M was more than three times year-end cash of$16.9M . At the same time, liabilities were only$13.7M and financing inflow was$25.7M , showing the company is keeping the balance sheet clean by returning to capital markets instead of adding debt.
Losses and cash burn are moving together, which points to better earnings quality than an early-stage company whose accounting loss is distorted by large non-cash items. In FY2025, net loss of
Spending mix shifted back toward research in FY2025: R&D climbed to
Financial Health Signals
Design Therapeutics, Inc. does not currently provide enough eligible data for a peer-relative financial health score, so none is published. The signals and metrics below are current.
Design Therapeutics, Inc. scores 39.86, well above the 2.99 safe threshold. The score is driven primarily by a large market capitalization ($953.1M) relative to total liabilities ($13.7M). This indicates low bankruptcy risk based on profitability, leverage, and asset efficiency.
Distress-screening estimate for non-financial companies. Not computed for banks or insurers, where the Altman model does not apply.
Design Therapeutics, Inc. passes 1 of 7 computable financial strength tests (2 of the nine could not be computed from available data). 1 of 4 profitability signals pass, no leverage/liquidity signals pass (rising debt, declining liquidity, or share dilution), neither operating efficiency signal passes.
Design Therapeutics, Inc. reported a net loss of $69.8M while operations used $54.4M of cash. With neither figure positive, the ratio between the two carries no quality signal.
Key Financial Metrics
Earnings & Revenue
Design Therapeutics, Inc. generated $0 in revenue in fiscal year 2025.
Design Therapeutics, Inc.'s EBITDA was -$78.8M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization. This represents a decrease of 27.6% from the prior year.
Design Therapeutics, Inc. reported -$69.8M in net income in fiscal year 2025. This represents a decrease of 40.7% from the prior year.
Design Therapeutics, Inc. earned -$1.22 per diluted share (EPS) in fiscal year 2025. This represents a decrease of 38.6% from the prior year.
Cash & Balance Sheet
Design Therapeutics, Inc. recorded an outflow of $54.6M in free cash flow in fiscal year 2025, representing a cash shortfall after capex. This represents a decrease of 25.6% from the prior year.
Design Therapeutics, Inc. held $16.9M in cash as of fiscal year 2025; long-term debt is not reported for that period.
Not reported for fiscal year 2025.
Margins & Returns
Design Therapeutics, Inc.'s ROE was -32.8% in fiscal year 2025, measuring profit generated per dollar of shareholder equity. This is down 12.4 percentage points from the prior year.
Not reported for fiscal year 2025.
Not reported for fiscal year 2025.
Not reported for fiscal year 2025.
Capital Allocation
Design Therapeutics, Inc. invested $59.1M in research and development in fiscal year 2025. This represents an increase of 33.3% from the prior year.
Design Therapeutics, Inc. invested $193K in capex in fiscal year 2025, funding long-term assets and infrastructure. This represents a decrease of 43.2% from the prior year.
Not reported for fiscal year 2025.
DSGN Income Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.
| Metric | TTM | FY25 | FY24 | FY23 | FY22 | FY21 | FY20 |
|---|---|---|---|---|---|---|---|
| Revenue | N/A | $0 | $0 | N/A | N/A | N/A | $226K |
| R&D Expenses | N/A | $59.1M+33.3% | $44.4M-22.3% | $57.1M+17.4% | $48.6M+96.2% | $24.8M+308.9% | $6.1M |
| SG&A Expenses | N/A | $20.3M+12.8% | $18.0M-14.6% | $21.1M+11.3% | $19.0M+71.7% | $11.1M+342.8% | $2.5M |
| Operating Income | N/A | -$79.5M-27.4% | -$62.4M+20.2% | -$78.2M-15.7% | -$67.6M-88.6% | -$35.8M-330.1% | -$8.3M |
| Income Tax | N/A | $0 | $0 | N/A | N/A | N/A | N/A |
| Net Income | N/A | -$69.8M-40.7% | -$49.6M+25.8% | -$66.9M-5.6% | -$63.3M-78.2% | -$35.5M-329.1% | -$8.3M |
| EPS (Diluted) | — | -$1.22-38.6% | -$0.88+26.1% | -$1.19-4.4% | -$1.14-48.1% | -$0.77 | N/A |
Not reported in any period shown, so not listed: Cost of Revenue, Gross Profit, Interest Expense.
TTM is the trailing twelve months, Q3 FY2025 through Q2 FY2026, summed from the four most recent quarterly filings. A row marked — cannot be summed at all, because a quarter in the window reports no per-share figure; a row marked N/A could be summed, but a quarter in the window does not report that metric.
DSGN Balance Sheet
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.
| Metric | FY25 | FY24 | FY23 | FY22 | FY21 | FY20 |
|---|---|---|---|---|---|---|
| Total Assets | $226.2M-10.3% | $252.1M-13.0% | $289.6M-15.1% | $341.1M-12.7% | $390.6M+969.6% | $36.5M |
| Current Assets | $223.8M-9.8% | $248.0M-12.8% | $284.6M-15.1% | $335.1M-13.1% | $385.4M+963.8% | $36.2M |
| Cash & Equivalents | $16.9M-25.3% | $22.6M+6.4% | $21.2M-20.0% | $26.5M-91.1% | $298.6M+12450.2% | $2.4M |
| Total Liabilities | $13.7M+37.1% | $10.0M-16.4% | $12.0M-13.5% | $13.8M+64.1% | $8.4M-82.4% | $47.8M |
| Current Liabilities | $13.1M+54.3% | $8.5M-12.1% | $9.6M-10.7% | $10.8M+104.0% | $5.3M+126.7% | $2.3M |
| Total Equity | $212.5M-12.2% | $242.1M-12.8% | $277.7M-15.2% | $327.3M-14.3% | $382.1M+3477.2% | -$11.3M |
| Retained Earnings | -$297.0M-30.7% | -$227.2M-27.9% | -$177.6M-60.4% | -$110.8M-133.4% | -$47.5M-298.0% | -$11.9M |
Not reported in any period shown, so not listed: Inventory, Accounts Receivable, Goodwill, Long-Term Debt.
DSGN Cash Flow Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.
| Metric | TTM | FY25 | FY24 | FY23 | FY22 | FY21 | FY20 |
|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$55.1M | -$54.4M-26.1% | -$43.1M+26.4% | -$58.6M-14.1% | -$51.3M-74.7% | -$29.4M-238.9% | -$8.7M |
| Capital Expenditures | $55K | $193K-43.2% | $340K+32.8% | $256K-72.1% | $918K-40.3% | $1.5M+1923.7% | $76K |
| Free Cash Flow | -$55.1M | -$54.6M-25.6% | -$43.4M+26.1% | -$58.8M-12.6% | -$52.2M-69.0% | -$30.9M-253.5% | -$8.7M |
| Investing Cash Flow | $2.4M | $22.9M-47.9% | $44.0M-16.3% | $52.5M+123.8% | -$221.0M-312.0% | -$53.6M-59.8% | -$33.6M |
| Financing Cash Flow | $45.9M | $25.7M+4917.2% | $513K-29.1% | $724K+208.1% | $235K-99.9% | $379.2M+751.5% | $44.5M |
Not reported in any period shown, so not listed: Dividends Paid, Share Buybacks.
TTM is the trailing twelve months, Q3 FY2025 through Q2 FY2026, summed from the four most recent quarterly filings. A row marked — cannot be summed at all, because a quarter in the window reports no per-share figure; a row marked N/A could be summed, but a quarter in the window does not report that metric.
DSGN Financial Ratios
Margins and returns are percentages; the remaining ratios are unitless multiples.
| Metric | FY25 | FY24 | FY23 | FY22 | FY21 | FY20 |
|---|---|---|---|---|---|---|
| Operating Margin | N/A | N/A | N/A | N/A | N/A | -3685.8% |
| Net Margin | N/A | N/A | N/A | N/A | N/A | -3663.7% |
| Return on Equity | -32.8%-12.4pp | -20.5%+3.6pp | -24.1%-4.7pp | -19.3%-10.0pp | -9.3% | N/A |
| Return on Assets | -30.9%-11.2pp | -19.7%+3.4pp | -23.1%-4.5pp | -18.6%-9.5pp | -9.1%+13.6pp | -22.7% |
| Current Ratio | 17.14-12.2x | 29.31-0.3x | 29.58-1.5x | 31.10-41.9x | 72.96+57.4x | 15.55 |
| Debt-to-Equity | 0.060.0x | 0.040.0x | 0.040.0x | 0.040.0x | 0.02 | N/A |
| FCF Margin | N/A | N/A | N/A | N/A | N/A | -3869.5% |
Not reported in any period shown, so not listed: Gross Margin.
Reported as filed but not readable as a share of revenue in the periods where the ratio runs further from zero than a revenue base allows; no change figure is given where either compared period is one of those: Operating Margin, Net Margin, FCF Margin.
Similar Companies
Where Design Therapeutics, Inc. Ranks
Frequently Asked Questions
What is Design Therapeutics, Inc.'s annual revenue?
Design Therapeutics, Inc. (DSGN) reported $0 in total revenue for fiscal year 2025. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.
Is Design Therapeutics, Inc. profitable?
No, Design Therapeutics, Inc. (DSGN) reported a net income of -$69.8M in fiscal year 2025.
What is Design Therapeutics, Inc.'s EBITDA?
Design Therapeutics, Inc. (DSGN) had EBITDA of -$78.8M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.
What is Design Therapeutics, Inc.'s return on equity (ROE)?
Design Therapeutics, Inc. (DSGN) has a return on equity of -32.8% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.
What is Design Therapeutics, Inc.'s free cash flow?
Design Therapeutics, Inc. (DSGN) recorded an outflow of $54.6M in free cash flow during fiscal year 2025. This represents a -25.6% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.
What is Design Therapeutics, Inc.'s operating cash flow?
Design Therapeutics, Inc. (DSGN) recorded an outflow of $54.4M in operating cash flow during fiscal year 2025, representing cash used by core business activities.
What are Design Therapeutics, Inc.'s total assets?
Design Therapeutics, Inc. (DSGN) had $226.2M in total assets as of fiscal year 2025, including both current and long-term assets.
What are Design Therapeutics, Inc.'s capital expenditures?
Design Therapeutics, Inc. (DSGN) invested $193K in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.
How much does Design Therapeutics, Inc. spend on research and development?
Design Therapeutics, Inc. (DSGN) invested $59.1M in research and development during fiscal year 2025.
What is Design Therapeutics, Inc.'s current ratio?
Design Therapeutics, Inc. (DSGN) had a current ratio of 17.14 as of fiscal year 2025, which is generally considered healthy.
What is Design Therapeutics, Inc.'s debt-to-equity ratio?
Design Therapeutics, Inc. (DSGN) had a debt-to-equity ratio of 0.06 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is Design Therapeutics, Inc.'s return on assets (ROA)?
Design Therapeutics, Inc. (DSGN) had a return on assets of -30.9% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.
What is Design Therapeutics, Inc.'s cash runway?
Based on fiscal year 2025 data, Design Therapeutics, Inc. (DSGN) had $16.9M in cash against an annual operating cash burn of $54.4M. This gives an estimated cash runway of approximately 4 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.
What is Design Therapeutics, Inc.'s Altman Z-Score?
Design Therapeutics, Inc. (DSGN) has an Altman Z-Score of 39.86, placing it in the Safe Zone (low bankruptcy risk). The Z-Score combines five financial ratios (working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets) to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.
What is Design Therapeutics, Inc.'s Piotroski F-Score?
Design Therapeutics, Inc. (DSGN) has a Piotroski F-Score of 1 out of 7 computable signals; 2 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are Design Therapeutics, Inc.'s earnings high quality?
Design Therapeutics, Inc. (DSGN) reported a net loss of $69.8M while operations used $54.4M of cash. With neither figure positive, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.